- Home
- NEOV vs VRCA Comparison
NEOV vs VRCA Comparison
Compare NEOV & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- VRCA
- Stock Information
- Founded
- NEOV 2018
- VRCA 2013
- Country
- NEOV United States
- VRCA United States
- Employees
- NEOV N/A
- VRCA N/A
- Industry
- NEOV Industrial Machinery/Components
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- VRCA Health Care
- Exchange
- NEOV Nasdaq
- VRCA Nasdaq
- Market Cap
- NEOV 72.2M
- VRCA 65.4M
- IPO Year
- NEOV N/A
- VRCA 2018
- Fundamental
- Price
- NEOV $4.52
- VRCA $0.80
- Analyst Decision
- NEOV Strong Buy
- VRCA Hold
- Analyst Count
- NEOV 1
- VRCA 5
- Target Price
- NEOV $7.50
- VRCA $6.00
- AVG Volume (30 Days)
- NEOV 197.3K
- VRCA 763.3K
- Earning Date
- NEOV 05-09-2025
- VRCA 08-13-2025
- Dividend Yield
- NEOV N/A
- VRCA N/A
- EPS Growth
- NEOV N/A
- VRCA N/A
- EPS
- NEOV N/A
- VRCA N/A
- Revenue
- NEOV $4,255,136.00
- VRCA $7,179,000.00
- Revenue This Year
- NEOV $208.50
- VRCA $171.87
- Revenue Next Year
- NEOV $128.75
- VRCA $71.38
- P/E Ratio
- NEOV N/A
- VRCA N/A
- Revenue Growth
- NEOV 52.64
- VRCA N/A
- 52 Week Low
- NEOV $1.80
- VRCA $0.38
- 52 Week High
- NEOV $6.11
- VRCA $8.98
- Technical
- Relative Strength Index (RSI)
- NEOV 75.13
- VRCA 61.35
- Support Level
- NEOV $3.10
- VRCA $0.72
- Resistance Level
- NEOV $4.75
- VRCA $0.67
- Average True Range (ATR)
- NEOV 0.35
- VRCA 0.10
- MACD
- NEOV 0.14
- VRCA 0.02
- Stochastic Oscillator
- NEOV 89.94
- VRCA 64.43
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.